YMMUNOBIO
Ymmunobio is a preclinical-stage oncology biotech startup committed to creating advanced cancer patient treatments. It makes extensive progress in developing antibodies that have an influence on the immune system by reinstating its immune response to cancers or directly inhibiting cancer cell proliferation.
YMMUNOBIO
Industry:
Biotechnology Medical Product Research
Founded:
2021-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.ymmunobio.com
Total Employee:
1+
Status:
Active
Total Funding:
1.4 M USD
Technology used in webpage:
Euro Wix
Similar Organizations
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Cabaletta Bio
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Coriell Life Sciences
Coriell Life Sciences delivers the power of precision medicine using pharmacogenomics and clinical decision support software.
ExpressCells
ExpressCells creates custom cell lines for biological research and drug discovery.
KetoSwiss
KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Vivodyne
Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies.
Official Site Inspections
http://www.ymmunobio.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.171
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Ymmunobio"
HOME | Ymmunobio
At Ymmunobio, our research is based on our deep understanding of immuno-oncology and precision cancer treatments. We leverage our profound knowledge of biologics, focusing on …See details»
ABOUT US | Ymmunobio
Ymmunobio is committed to developing preclinical breakthroughs toward improving how cancer therapies are developed. Dr. Katrin Rupalla & Dr. Peter Schiemann co-founded Ymmunobio in 2021 as a way to advance …See details»
Ymmunobio - Crunchbase Company Profile & Funding
Ymmunobio is a preclinical-stage oncology biotech startup committed to creating advanced cancer patient treatments. It makes extensive progress in …See details»
Ymmunobio AG - Swiss Biotech
Ymmunobio AG is a preclinical stage biotechnology company developing first in class assets for the treatment of solid tumors. Products, services, technology …See details»
Ymmunobio - LinkedIn
Ymmunobio is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies.See details»
Ymmunobio AG Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Ymmunobio AG of Riehen, BASEL-STADT. Get the latest business insights from Dun & Bradstreet.See details»
Ymmunobio 2025 Company Profile: Valuation, Funding
Ymmunobio General Information Description. Operator of a preclinical-stage biotechnology platform intended to develop novel antibody-based cancer therapies. The company's platform …See details»
Ymmunobio - Products, Competitors, Financials, Employees, …
Ymmunobio operates as a preclinical-stage biotechnology company specializing in the development of innovative cancer therapies. Use the CB Insights Platform to explore …See details»
Ymmunobio: The Venture Leader Biotech developing on first-in …
May 13, 2024 Ymmunobio is developing treatments for solid tumors, addressing a significant unmet need in conditions like liver and gastric cancer, where current treatment options are …See details»
Ymmunobio - Contacts, Employees, Board Members, Advisors
Ymmunobio is a preclinical-stage oncology biotech startup committed to creating advanced cancer patient treatments. ... Log In. Log In. Experience the new Crunchbase, powered by AI . …See details»
Ymmunobio - Overview, News & Similar companies | ZoomInfo.com
Ymmunobio is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new class es of antibodies. Those …See details»
Ymmunobio AG - Venturelab
Ymmunobio has built a complete development program around this novel target featuring three therapeutic antibodies: 1. YB-800ADC, an ADC with linkers of the 3rd generation 2. YB …See details»
Ymmunobio secures $1.4M seed funding - startupticker.ch
Nov 14, 2023 Ymmunobio is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies …See details»
Advancing Immunotherapy: Insights from Ymmunobio CEO
Nov 27, 2024 Peter Schiemann: At Ymmunobio, we are pioneering the development of targeted immunotherapies by identifying a novel tumor target with exceptional properties. This target is …See details»
Ymmunobio gets ownership rights to NPTXR antibodies
Jan 31, 2023 Ymmunobio Founder and CEO Katrin Rupalla stated that the ownership of NPTXR is a major advance for the company. In a press release, she noted that YB-800 targets cancer …See details»
Ymmunobio Welcomes Dr. Kanda and Dr. Khairnar to Advisory Board
Mar 2, 2023 Ymmunobio is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies. …See details»
Ymmunobio gets license ownership from Nagoya University for …
Ymmunobio signed the transfer ownership agreement in 2022 with Nagoya University for the license to NPTXR antibodies, which were invented by Professor Mitsuro Kanda, Department of …See details»
Ymmunobio and the Paul Scherrer Institute win Innosuisse …
Jan 17, 2025 Ymmunobio is at the forefront of oncology research, focusing on a novel target receptor for the treatment of solid tumors with high unmet need. Currently, in pre-clinical …See details»
YB-800 ADCs Reach Important Milestone: Proof of Concept in …
3 days ago RIEHEN, Switzerland, April 18, 2025 /PRNewswire/ -- Ymmunobio AG (YB), a Swiss-based global biotech company dedicated to the development of new cancer …See details»
Ymmunobio Company Information - Funding, Investors, and More
Get information on funding, investors, industries, and more for Ymmunobio. See Ymmunobio company profile and funding data.See details»